Aerosolized clindamycin is superior to aerosolized dexamethasone or clindamycin-dexamethasone combination in the treatment of severe Porphyromonas gingivalis aspiration pneumonia in an experimental murine model

Experimental Lung Research

Volumn 38, Issue 1, 2012, Pages 9-18

  Nemec, Ana ^a,b   Pavlica, Zlatko ^a   Nemec Svete, Alenka ^a   Eržen, Damijan ^c   Milutinovia, Aleksandra ^a   Petelin, Milan ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

Author keywords

Aspiration pneumonia; Clindamycin; Cytokines; Dexamethasone; P. gingivalis

Indexed keywords

CLINDAMYCIN; DEXAMETHASONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPIRATION PNEUMONIA; BRONCHOPNEUMONIA; CONTROLLED STUDY; GRAM NEGATIVE INFECTION; HISTOPATHOLOGY; LUNG; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PORPHYROMONAS GINGIVALIS; PORPHYROMONAS INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TISSUE LEVEL;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-BACTERIAL AGENTS; BACTEROIDACEAE INFECTIONS; BRONCHOPNEUMONIA; CHEMOTHERAPY, ADJUVANT; CLINDAMYCIN; DEXAMETHASONE; DISEASE MODELS, ANIMAL; INTERLEUKIN-1BETA; INTERLEUKIN-6; LUNG; MALE; MICE; MICE, INBRED BALB C; NASAL SPRAYS; PNEUMONIA, ASPIRATION; PORPHYROMONAS GINGIVALIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855427641     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2011.632063     Document Type: Article

References (39)

1. Sibila O, Agusti C, Torres A: Corticosteroids in severe pneumonia. Eur Respir J. 2008;32:259-264.
2. Wunderink RG: Adjunctive therapy in community-acquired pneumonia. Semin Respir Crit Care Med. 2009;30:146-153.
3. American Thoracic Society: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
4. Falguera M, Carratala J, Ruiz-Gonzalez A, Garcia-Vidal C, Gazquez I, Dorca J, et al.: Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. Respirology. 2009;14:105-111.
5. Paju S, Scannapieco FA: Oral biofilms, periodontitis, and pulmonary infections. Oral Dis. 2007;13:508-512. (Pubitemid 47609899)
6. Okuda K, Kimizuka R, Abe S, Kato T, Ishihara K: Involvement of periodontopathic anaerobes in aspiration pneumonia. J Periodontol. 2005;76:2154-2160. (Pubitemid 41748965)
7. Terpenning MS, Taylor GW, Lopatin DE, Kerr CK, Dominguez BL, Loesche WJ: Aspiration pneumonia: dental and oral risk factors in an older veteran population. J Am Geriatr Soc. 2001;49:557-563. (Pubitemid 32525025)
8. Hajishengallis G, Wang M, Bagby GJ, Nelson S: Importance of TLR2 in early innate immune response to acute pulmonary infection with Porphyromonas gingivalis in mice. J Immunol. 2008;181:4141-4149.
9. Gendron R, Grenier D, Maheu-Robert L: The oral cavity as a reservoir of bacterial pathogens for focal infections. Microbes Infect. 2000;2:897-906. (Pubitemid 30483185)
10. Awano S, Ansai T, Takata Y, Soh I, Akifusa S, Hamasaki T, et al.: Oral health and mortality risk from pneumonia in the elderly. J Dent Res. 2008;87:334-339.
11. Kimizuka R, Kato T, Ishihara K, Okuda K: Mixed infections with Porphyromonas gingivalis and Treponema denticola cause excessive inflammatory responses in a mouse pneumonia model compared with monoinfections. Microbes Infect. 2003;5:1357-1362. (Pubitemid 37510362)
12. Nemec A, Pavlica Z, Nemec-Svete A, Erzen D, Crossley DA, Petelin M: Lack of soluble tumor necrosis factor alpha receptor 1 and 2 and interleukin-1? compartmentalization in lungs of mice after a single intratracheal inoculation with live Porphyromonas gingivalis. Exp Lung Res. 2009;35:605-620.
13. Siempos II, Vardakas KZ, Kopterides P, Falagas ME: Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother. 2008;62:661-668.
14. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG: Efficacy of corticosteroids in communityacquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181:975-982.
15. Wijagkanalan W, Higuchi Y, Kawakami S, Teshima M, Sasaki H, Hashida M: Enhanced anti-inflammation of inhaled dexamethasone palmitate using mannosylated liposomes in an endotoxin-induced lung inflammation model. Mol Pharmacol. 2008;74:1183-1192.
16. Mizgerd JP: Acute lower respiratory tract infection. N Engl J Med. 2008;358:716-727.
17. Pavlica Z, Nemec A, Nemec A, Er?zen D, Crossley DA, Petelin M: Local and systemic up-regulation of TNF?, IL-1? and IL-6 in mice intratracheally inoculated with Porphyromonas gingivalis. Acta Vet Brno. 2008;77:377-385.
18. Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz K, et al.: The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis. 2008;198:1180-1188.
19. Hale KK, Smith CG, Baker SL, Vanderslice RW, Squires CH, Gleason TM, et al.: Multifunctional regulation of the biological effects of TNF-alpha by the soluble type I and type II TNF receptors. Cytokine. 1995;7:26-38.
20. Mukhopadhyay S, Hoidal JR, Mukherjee TK: Role of TNFalpha in pulmonary pathophysiology. Respir Res. 2006;7:125.
21. Agusti C, Rano A, Filella X, Gonzalez J, Moreno A, Xaubet A, et al.: Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest. 2003;123:488-498. (Pubitemid 36269435)
22. Monton C, Ewig S, Torres A, El-Ebiary M, Filella X, Rano A, et al.: Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J. 1999;14:218-220. (Pubitemid 29411261)
23. Sibila O, Luna CM, Agusti C, Baquero S, Gando S, Patron JR, et al.: Effects of glucocorticoids in ventilated piglets with severe pneumonia. Eur Respir J. 2008;32:1037-1046.
24. Garcia-Vidal C, Carratala J, Fernandez-Sabe N, Dorca J, Verdaguer R, Manresa F, et al.: Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clin Microbiol Infect. 2009;15:1033-1038.
25. Yende S, D'Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, et al.: Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med. 2008;177:1242-1247. (Pubitemid 351860933)
26. Kulik EM, Lenkeit K, Chenaux S, Meyer J: Antimicrobial susceptibility of periodontopathogenic bacteria. J Antimicrob Chemother. 2008;61:1087-1091. (Pubitemid 351524454)
27. Ardila CM, Granada MI, Guzman IC: Antibiotic resistance of subgingival species in chronic periodontitis patients. J Periodontal Res. 2010;45:557-563.
28. Kadowaki M, Demura Y, Mizuno S, Uesaka D, Ameshima S, Miyamori I, et al.: Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients. Chest. 2005;127:1276-1282. (Pubitemid 46224291)
29. Allewelt M, Schuler P, Bolcskei PL, Mauch H, Lode H: Ampicillin + sulbactam vs clindamycin +/? cephalosporin for the treatment of aspiration pneumonia and primary lung abscess. Clin Microbiol Infect. 2004;10:163-170. (Pubitemid 38256520)
30. Johnson JL, Hirsch CS: Aspiration pneumonia. Recognizing and managing a potentially growing disorder. Postgrad Med. 2003;113:99-102, 105-106, 111-112.
31. Ioanas M, Ferrer M, Cavalcanti M, Ferrer R, Ewig S, Filella X, et al.: Causes and predictors of nonresponse to treatment of intensive care unit-acquired pneumonia. Crit Care Med. 2004;32:938-945. (Pubitemid 38471513)
32. Nelson S, Bagby GJ, Bainton BG, Wilson LA, Thompson JJ, Summer WR: Compartmentalization of intraalveolar and systemic lipopolysaccharide-induced tumor necrosis factor and the pulmonary inflammatory response. J Infect Dis. 1989;159:189-194. (Pubitemid 19049356)
33. Igonin AA, Armstrong VW, Shipkova M, Lazareva NB, Kukes VG, Oellerich M: Circulating cytokines as markers of systemic inflammatory response in severe community-acquired pneumonia. Clin Biochem. 2004;37:204-209. (Pubitemid 38221568)
34. Deng JC, Standiford TJ: The systemic response to lung infection. Clin Chest Med. 2005;26:1-9. (Pubitemid 40410697)
35. Tutor JD, Mason CM, Dobard E, Beckerman RC, Summer WR, Nelson S: Loss of compartmentalization of alveolar tumor necrosis factor after lung injury. Am J Respir Crit Care Med. 1994;149:1107-1111. (Pubitemid 24147046)
36. Seki H, Fukunaga K, AritaM, Arai H, Nakanishi H, Taguchi R, et al.: The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J Immunol. 2010;184:836-843.
37. Di Paola R,Mazzon E,Muia C, Crisafulli C, Terrana D, Greco S, et al.: Effects of etanercept, a tumour necrosis factor-alpha antagonist, in an experimental model of periodontitis in rats. Br J Pharmacol. 2007;150:286-297. (Pubitemid 46221038)
38. Yanik GA, Ho VT, Levine JE, White ES, Braun T, Antin JH, et al.: The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood. 2008;112:3073-3081.
39. Patial S, Parameswaran N: Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010;20:87-103.